
Please try another search
(Reuters) - U.S. lawmakers have requested data and documents from the Food and Drug Administration (FDA) related to its accelerated approval of Biogen Inc (NASDAQ:BIIB)'s new Alzheimer's drug, mounting further pressure on the agency that has come under fire for clearing the drug.
The chairs of the House Committee on Oversight and Reform and the Committee on Energy and Commerce have requested the FDA to disclose documents related to the interactions between Biogen and the agency's staff.
"We are concerned by apparent anomalies in FDA's processes surrounding its review of Aduhelm," chairs of the two committee wrote in a letter to the agency.
The committees had launched an investigation following the drug's approval on June 7 that had sparked controversy and concerns over the FDA's process, as a panel of its outside advisers had recommended against the approval.
The letter, dated Sept. 1, also requests for details on the agency's process for approving a therapy when there is a disagreement between the FDA staff and its panel of external advisers, known as the advisory committee.
Biogen said it was continuing to cooperate with the committees' investigation and had produced documents as and when requested.
An independent federal review was launched last month into the accelerated approval pathway used by the drug regulator to approve the treatment, on the request of the FDA's acting commissioner Janet Woodcock.
LOS ANGELES (Reuters) - The latest season of Netflix Inc (NASDAQ:NFLX)'s "Stranger Things" has pushed total viewership for the series to more than 1.15 billion hours, the...
By Jonathan Stempel and Jessica DiNapoli NEW YORK (Reuters) - Ben & Jerry's on Tuesday sued its parent Unilever (NYSE:UL) Plc to block the sale of its Israeli business to a local...
By Liz Moyer Investing.com -- Energy shares sold off sharply on Tuesday after crude oil prices plunged 10%, with WTI falling below $100 a barrel. Oil majors felt the hit, with...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.